BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19035176)

  • 1. [Prognostic significance of p53 and ATM gene deletion in patients with chronic lymphocytic leukemia].
    Xu W; Li JY; Li L; Wu YJ; Yu H; Shen QD; Qiu HX
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):450-3. PubMed ID: 19035176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
    Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
    Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia.
    Ripollés L; Ortega M; Ortuño F; González A; Losada J; Ojanguren J; Soler JA; Bergua J; Coll MD; Caballín MR
    Cancer Genet Cytogenet; 2006 Nov; 171(1):57-64. PubMed ID: 17074592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
    Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
    Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.
    Haferlach C; Dicker F; Weiss T; Schnittger S; Beck C; Grote-Metke A; Oruzio D; Kern W; Haferlach T
    Genes Chromosomes Cancer; 2010 Sep; 49(9):851-9. PubMed ID: 20552631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
    Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Bardi A; Cavazzini F; Milani R; Minotto C; Tieghi A; Della Porta M; Agostini P; Tammiso E; Negrini M; Castoldi G
    Haematologica; 2002 Jan; 87(1):44-51. PubMed ID: 11801464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.
    Joshi AD; Dickinson JD; Hegde GV; Sanger WG; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
    Cancer Genet Cytogenet; 2007 Jan; 172(2):120-6. PubMed ID: 17213020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryptic deletion involving the ATM locus at 11q22.3 approximately q23.1 in B-cell chronic lymphocytic leukemia and related disorders.
    Eclache V; Caulet-Maugendre S; Poirel HA; Djemai M; Robert J; Lejeune F; Raphaël M
    Cancer Genet Cytogenet; 2004 Jul; 152(1):72-6. PubMed ID: 15193446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia.
    Joshi AD; Hegde GV; Dickinson JD; Mittal AK; Lynch JC; Eudy JD; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5295-304. PubMed ID: 17875758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment.
    Trbusek M; Malcikova J; Smardova J; Kuhrova V; Mentzlova D; Francova H; Bukovska S; Svitakova M; Kuglik P; Linkova V; Doubek M; Brychtova Y; Zacal J; Kujickova J; Pospisilova S; Dvorakova D; Vorlicek J; Mayer J
    Leukemia; 2006 Jun; 20(6):1159-61. PubMed ID: 16572201
    [No Abstract]   [Full Text] [Related]  

  • 11. A new minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia.
    Gardiner A; Parker H; Glide S; Mould S; Robinson H; Tracy I; Stankovic T; Oscier D; Strefford J
    Leuk Res; 2012 Mar; 36(3):307-10. PubMed ID: 21955805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased transferrin receptor expression following 11q23 deletion as a mechanism of malignant progression in chronic lymphocytic leukemia.
    Shackelford RE; Bhalodia AR; Cotelingam JD; Veillon DM; Lowery-Nordberg M
    Med Hypotheses; 2006; 66(3):509-12. PubMed ID: 16326028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.
    Carter A; Lin K; Sherrington PD; Atherton M; Pearson K; Douglas A; Burford A; Brito-Babapulle V; Matutes E; Catovsky D; Pettitt AR
    Leukemia; 2006 Apr; 20(4):737-40. PubMed ID: 16437137
    [No Abstract]   [Full Text] [Related]  

  • 14. A putative "hepitype" in the ATM gene associated with chronic lymphocytic leukemia risk.
    Martín-Guerrero I; Enjuanes A; Richter J; Ammerpohl O; Colomer D; Ardanaz M; Marco F; Salas A; Campo E; Siebert R; García-Orad A
    Genes Chromosomes Cancer; 2011 Nov; 50(11):887-95. PubMed ID: 21910157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia.
    Del Principe MI; Del Poeta G; Venditti A; Buccisano F; Maurillo L; Marini R; Cox MC; Panetta P; Suppo G; Degan M; Bruno A; Gattei V; Amadori S
    Haematologica; 2004 Dec; 89(12):1468-75. PubMed ID: 15590397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia.
    Herholz H; Kern W; Schnittger S; Haferlach T; Dicker F; Haferlach C
    Cancer Genet Cytogenet; 2007 Apr; 174(1):57-60. PubMed ID: 17350468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of p53 gene deletion in Xinjiang patients with chronic lymphocytic leukemia by fluorescence in situ hybridization and its clinical significance].
    Maimaitili Y; Guzailinuer W; Wang X; Liu H; Li Y; Xiao M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Aug; 31(4):499-503. PubMed ID: 25119920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of chromosomal abnormalities relevant to prognosis in chronic lymphocytic leukemia using multiplex ligation-dependent probe amplification.
    Stevens-Kroef M; Simons A; Gorissen H; Feuth T; Weghuis DO; Buijs A; Raymakers R; Geurts van Kessel A
    Cancer Genet Cytogenet; 2009 Dec; 195(2):97-104. PubMed ID: 19963108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of molecular cytogenetic abnormalities in 30 patients with chronic lymphocytic leukemia by fluorescence in situ hybridization].
    Dai D; Zhang XQ; Zhang XZ; Su AL; Zhang L; Cao SB; Xu YL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):31-5. PubMed ID: 19236742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.